Company news: Eli Lilly

Share this article:
Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes,  met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin. The most frequently reported adverse events were gastrointestinal-related and consistent with prior studies, said the company. A number of additional studies are ongoing as part of the AWARD battery.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.